{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:55:22Z","timestamp":1781780122569,"version":"3.54.5"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Chemo-immunotherapy is standard of care for women with recurrent or advanced mismatch repair deficient endometrial carcinoma. However, it is uncertain whether patients with mismatch repair deficient advanced or recurrent endometrial carcinoma derive less benefit from chemotherapy than those with mismatch repair proficient endometrial carcinoma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a meta-analysis of randomized controlled trials (RCTs) in advanced or recurrent endometrial carcinoma to determine the difference in the benefit of chemotherapy in mismatch repair deficient vs mismatch repair proficient endometrial carcinoma. Data on chemotherapy outcomes including objective response rate, progression-free survival (PFS), and overall survival were retrieved. We pooled these data using the inverse variance method and examined subgroup difference by mismatch repair status. We also compared differences in PFS and overall survival outcomes by creating individual patient data from the Kaplan\u2013Meier curves of trial publications for sensitivity analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 5 RCTs with 1137 participants (mismatch repair deficient, 26%; mismatch repair proficient, 74%) were included. All participants were treated with carboplatin-based chemotherapy. There was no difference between the mismatch repair deficient and mismatch repair proficient subgroups for objective response rate (66.5% vs 64.0%; P\u2009=\u2009.20 for subgroup difference), PFS (hazard ratio [HR] = 0.93, 95% confidence interval [CI] = 0.77 to 1.12; P\u2009=\u2009.44; median PFS = 7.6 vs 9.5\u2009months) or overall survival (HR = 1.03, 95% CI = 0.73 to 1.44; P\u2009=\u2009.88; median overall survival = not reached vs 28.6\u2009months).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Objective response rate, PFS, and overall survival were similar among those with mismatch repair deficient vs mismatch repair proficient endometrial cancer treated with front-line, platinum-doublet chemotherapy in RCTs. These findings reinforce the importance of combining chemotherapy together with immune checkpoint inhibitors until the results of trials comparing immune checkpoint therapy alone with combination therapy are available.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jncics\/pkae101","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T18:00:08Z","timestamp":1729533608000},"source":"Crossref","is-referenced-by-count":4,"title":["Impact of chemotherapy on patients with mismatch repair deficient advanced endometrial carcinomas\u2014a meta-analysis"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6570-9683","authenticated-orcid":false,"given":"Angelina","family":"Tjokrowidjaja","sequence":"first","affiliation":[{"name":"National Health and Medical Research Council Clinical Trials Centre, The University of Sydney , Sydney 2050,","place":["Australia"]},{"name":"Australia New Zealand Gynecological Oncology Group , Camperdown 2050,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4910-4615","authenticated-orcid":false,"given":"Peey-Sei","family":"Kok","sequence":"additional","affiliation":[{"name":"National Health and Medical Research Council Clinical Trials Centre, The University of Sydney , Sydney 2050,","place":["Australia"]},{"name":"Australia New Zealand Gynecological Oncology Group , Camperdown 2050,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6366-5523","authenticated-orcid":false,"given":"Yoland C","family":"Antill","sequence":"additional","affiliation":[{"name":"Australia New Zealand Gynecological Oncology Group , Camperdown 2050,","place":["Australia"]},{"name":"Faculty of Medicine, Dentistry and Health Sciences, Monash University , Carlton, VIC 3168,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3689-5956","authenticated-orcid":false,"given":"Clare L","family":"Scott","sequence":"additional","affiliation":[{"name":"Australia New Zealand Gynecological Oncology Group , Camperdown 2050,","place":["Australia"]},{"name":"Walter and Eliza Hall Institute of Medical Research , Parkville, VIC 3052,","place":["Australia"]},{"name":"Department of Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne , Parkville, VIC 3052,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6826-6014","authenticated-orcid":false,"given":"Linda R","family":"Mileshkin","sequence":"additional","affiliation":[{"name":"Australia New Zealand Gynecological Oncology Group , Camperdown 2050,","place":["Australia"]},{"name":"Department of Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne , Parkville, VIC 3052,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3090-795X","authenticated-orcid":false,"given":"Michael L","family":"Friedlander","sequence":"additional","affiliation":[{"name":"Australia New Zealand Gynecological Oncology Group , Camperdown 2050,","place":["Australia"]},{"name":"University of New South Wales Clinical School, Prince of Wales Hospital , Sydney 2033,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2955-9820","authenticated-orcid":false,"given":"Chee K","family":"Lee","sequence":"additional","affiliation":[{"name":"National Health and Medical Research Council Clinical Trials Centre, The University of Sydney , Sydney 2050,","place":["Australia"]},{"name":"Australia New Zealand Gynecological Oncology Group , Camperdown 2050,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"key":"2024111117004226100_pkae101-B1","author":"Abu-Rustum","year":"2024"},{"key":"2024111117004226100_pkae101-B2","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"key":"2024111117004226100_pkae101-B3","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med"},{"key":"2024111117004226100_pkae101-B4","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S1470-2045(23)00016-5","article-title":"Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"24","author":"Pignata","year":"2023","journal-title":"Lancet Oncol"},{"key":"2024111117004226100_pkae101-B5","doi-asserted-by":"crossref","first-page":"S1281","DOI":"10.1016\/j.annonc.2023.10.034","article-title":"LBA40 Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced\/recurrent endometrial carcinoma","volume":"34","author":"Colombo","year":"2023","journal-title":"Ann Oncol"},{"key":"2024111117004226100_pkae101-B6","doi-asserted-by":"crossref","first-page":"S1282","DOI":"10.1016\/j.annonc.2023.10.035","article-title":"LBA41 Durvalumab (durva) plus carboplatin\/paclitaxel (CP) followed by maintenance (mtx) durva & olaparib (ola) as a first-line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): results from the phase III DUO-E\/GOG-3041\/ENGOT-EN10 trial","volume":"34","author":"Westin","year":"2023","journal-title":"Annals of Oncology"},{"key":"2024111117004226100_pkae101-B7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J Clin Oncol"},{"key":"2024111117004226100_pkae101-B8","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Clin Oncol"},{"key":"2024111117004226100_pkae101-B9","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ygyno.2023.01.025","article-title":"Molecular subtype stratified outcomes according to adjuvant therapy in endometrial cancer","volume":"170","author":"Jamieson","year":"2023","journal-title":"Gynecol Oncol"},{"key":"2024111117004226100_pkae101-B10","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.3390\/cancers15143639","article-title":"Retrospective analysis of the correlation of MSI-h\/dMMR status and response to therapy for endometrial cancer: RAME study, a multicenter experience","volume":"15","author":"Tuninetti","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2024111117004226100_pkae101-B11","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/annonc\/mdl417","article-title":"Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration","volume":"18","author":"Humber","year":"2007","journal-title":"Ann Oncol"},{"key":"2024111117004226100_pkae101-B12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"2024111117004226100_pkae101-B13","doi-asserted-by":"crossref","first-page":"S1284","DOI":"10.1016\/j.annonc.2023.10.037","article-title":"LBA43 Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin\/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial","volume":"34","author":"Eskander","year":"2023","journal-title":"Ann Oncol"},{"key":"2024111117004226100_pkae101-B14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ygyno.2022.11.029","article-title":"Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)\/microsatellite instability high (MSI-high) endometrial carcinoma","volume":"169","author":"Colomba","year":"2023","journal-title":"Gynecol Oncol"},{"key":"2024111117004226100_pkae101-B15","doi-asserted-by":"crossref","first-page":"491","DOI":"10.21037\/atm-22-124","article-title":"The prognostic and predictive value of mismatch repair status in patients with locally advanced rectal cancer following neoadjuvant therapy","volume":"10","author":"Wu","year":"2022","journal-title":"Ann Transl Med"},{"key":"2024111117004226100_pkae101-B16","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1093\/annonc\/mdx052","article-title":"Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study","volume":"28","author":"Dienstmann","year":"2017","journal-title":"Ann Oncol"},{"key":"2024111117004226100_pkae101-B17","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2009.27.1825","article-title":"Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer","volume":"28","author":"Sargent","year":"2010","journal-title":"J Clin Oncol"},{"key":"2024111117004226100_pkae101-B18","doi-asserted-by":"crossref","first-page":"5939","DOI":"10.1158\/1078-0432.CCR-18-0412","article-title":"Clinical utility of prospective molecular characterization in advanced endometrial cancer","volume":"24","author":"Soumerai","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2024111117004226100_pkae101-B19","doi-asserted-by":"crossref","first-page":"TPS5623","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS5623","article-title":"KEYNOTE-C93\/GOG-3064\/ENGOT-en15: a phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma","volume":"40","author":"Slomovitz","year":"2022","journal-title":"J Clin Oncol"},{"key":"2024111117004226100_pkae101-B20","doi-asserted-by":"crossref","first-page":"TPS5630","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS5630","article-title":"Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced\/metastatic setting: DOMENICA study (GINECO-EN105b\/ENGOT-en13 study)","volume":"41","author":"Joly","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncics\/advance-article-pdf\/doi\/10.1093\/jncics\/pkae101\/59933676\/pkae101.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/8\/6\/pkae101\/60593943\/pkae101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/8\/6\/pkae101\/60593943\/pkae101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T17:01:17Z","timestamp":1731344477000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pkae101\/7829150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pkae101","relation":{},"ISSN":["2515-5091"],"issn-type":[{"value":"2515-5091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,10,21]]},"article-number":"pkae101"}}